A Phase 1 Open-Label, Single-Center Study to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Proliferative Diabetic Retinopathy (PDR)
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2016
At a glance
- Drugs PAN 90806 (Primary)
- Indications Diabetic retinopathy
- Focus Adverse reactions
- Sponsors PanOptica
- 27 Sep 2016 Status changed from active, no longer recruiting to completed.
- 24 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 24 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016 as reported ClinicalTrials.gov.